Experienced in Thrombocytopenia

Adrian E. Schmidt

Zurich, ZH, CH 
Experienced in Thrombocytopenia
Zurich, ZH, CH 
OverviewLocationsClinical Research

Overview

Adrian Schmidt practices in Zurich, Switzerland. Mr. Schmidt is rated as an Experienced expert by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Thrombocytopenia, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Vitrectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Thrombocytopenia.

Gender
Male

Locations

Zurich, ZH, Switzerland
Other Locations
Waid, ZH 8063, Switzerland
Switzerland
Basel, BS 4002, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
View 2 Less Clinical Trials

41 Total Publications

Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.
Journal: Swiss medical weekly
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schmidt's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile